Review
A mixed treatment comparison meta-analysis of antibiotic treatments for bovine respiratory disease

https://doi.org/10.1016/j.prevetmed.2012.11.025Get rights and content

Abstract

In this publication we use mixed treatment comparison meta-analysis to compare the efficacy of antibiotic treatments for bovine respiratory disease in beef cattle. Studies were eligible for the meta-analysis if they were publically available and reported the assessment of antibiotic protocols registered for use in the United States (US) for bovine respiratory disease (BRD) in beef cattle and were conducted in North America. Three electronic databases, the proceedings of two bovine specific conferences, pharmaceutical company web sites and the US Food and Drug Administration website were searched to identify relevant trials. The network of evidence used in the analysis contained 194 trial arms from 93 trials. Of the 93 trials there were 8 with three arms. The network of evidence contained information for 12 antibiotics. The output from the analysis provided information about the risk ratio comparing all possible treatments for BRD including comparisons based only on indirect data. The output also included a relative ranking of the treatments and estimates of the probability that an antibiotic protocol was the worst treatment option.

Introduction

Producers and veterinarians may legally choose from numerous registered antibiotics for the treatment of bovine respiratory disease (BRD). When deciding which antibiotic to use producers and veterinarians consider many factors including comparative efficacy. Ideally producers and veterinarians would conduct randomized controlled trials at the production site to compare the efficacy of the products, and make the treatment choice based on observed efficacy and cost. For owners of large feedlots and feedlot consultants this is a realistic approach to selection of treatment regimens. For other veterinarians and producers, conducting clinical trials may be difficult. In these situations, veterinarians and producers rely upon scientific literature to assess the efficacy of products. However, if the comparison of interest is not publically available veterinarians or producers must use indirect information to assess comparative efficacy. For example, if one trial compared regimen B to regimen A and reported a relative risk of failure of 0.5; i.e., B had half the failure rate of A, and a second trial compared regimen C to regimen A and reported a relative risk of failure of 0.25, many would conclude that C was twice as effective as B based on the indirect comparison of B vs. C. This approach to comparative efficacy is referred to as the naïve approach and can be misleading because it ignores study level factors and the unit of randomization (Glenny et al., 2005). The naïve approach also fails to empirically incorporate uncertainty about the within-trial direct estimates. For example, if the B vs. A trial used 1000 animals, while the C vs. A trial used 100 animals, the differences in uncertainty about the direct effects of B vs. A and C vs. A should be incorporated into the estimate of comparative efficacy.

A statistical alternative to the naïve approach for comparative efficacy is called mixed treatment comparison (MTC) meta-analysis, also known as network meta-analysis (Higgins and Whitehead, 1996, Jansen et al., 2008, Lu and Ades, 2004, Lumley, 2002, Salanti et al., 2008). The principle behind MTC meta-analysis is to use evidence from the full network of trial results to make inferences about comparative efficacy while addressing many concerns associated with the naïve approach (Higgins and Whitehead, 1996). Mixed treatment comparison meta-analysis combines direct and indirect estimates of efficacy using the network of information from trials, while accounting for lack of randomization at the study level. The use of mixed treatment comparisons meta-analysis is well established in human medicine but the approach remains rare in veterinary science (Jansen et al., 2011, Nixon et al., 2007, Numthavaj et al., 2011, Piccini and Kong, 2011, Steiner et al., 2012, Van den Bruel et al., 2011, Wang et al., 2010).

Our objective was to use MTC meta-analysis to compare the efficacy of BRD antibiotic treatments. The review question was “What is the comparative efficacy of antibiotics treatments registered for use in North America for the treatment of undifferentiated bovine respiratory disease in feedlot calves?” The rationale for the project was that the information from a MTC meta-analysis would help producers and veterinarians use the full network of publically available information for decision making about BRD treatment choices.

Section snippets

The review question

Review questions are often defined in terms of the population (P), intervention (I), comparator (C) and outcome (O), i.e., a PICO question, and we elaborated each aspect of the question using this approach. The population of interest (P) was calves with undifferentiated bovine respiratory disease in North American feedlots. Therefore, studies were considered eligible if they could reasonably be expected to exclude yearling aged animals. Many studies did not provide exact information about the

Results

The network of evidence used in the analysis contained 194 trial arms from 93 trials (Fig. 1). From 93 trials there were 8 with three arms. (Booker et al., 1997, Freedom of Information Summary, 1996, Freedom of Information Summary, 1988, Freedom of Information Summary, 1998a, Freedom of Information Summary, 1998b, Freedom of Information Summary, 1998c, Freedom of Information Summary, 2002, Freedom of Information Summary, 2003, Freedom of Information Summary, 2005, Freedom of Information

Discussion

The results of the MTC meta-analysis enable producers and veterinarians to obtain estimates of comparative efficacy that better describe uncertainty than naïve approaches to indirect comparisons (Fig. 2). For example, the estimated risk ratio comparing incidence of re-treatment in trials that assessed danofloxacin (numerator) to trial arms that assessed tulathromycin (denominator) is 1.32 (95% CI = 0.66, 2.43) suggesting that based on the publically available data there is no evidence that one

Funding

No direct grant support was used for this project.

Conflict of interest statement

Dr. O’Connor received a grant from Pfizer Animal Health to study an unrelated factor in 2010–2012. The other authors have no conflicts to declare.

Acknowledgements

Thank you to Dr. J. Higgins for addition assistance with the MTC analysis. Thank you to Stacie Gould for assistance with data extraction and manuscript preparation.

References (56)

  • Freedom of Information Summary, 1998c. NADA 141-086 Baytril 100 Injectable Solution – original approval....
  • Freedom of Information Summary, 2002. NADA 141-207 A180 Sterile Antimicrobial Injectable Solution....
  • Freedom of Information Summary, 2003. NADA 141-209 Nacxel XT Sterile Suspension – original approval....
  • Freedom of Information Summary, 2005. NADA 141-244 Draxxin Injectable Solution – original approval....
  • Freedom of Information Summary, 2006. NADA 141-244 Draxxin Injectable Solution....
  • Freedom of Information Summary, 2008. NADA 141-265 Nuflor Gold – original approval....
  • Freedom of Information Summary, 2009. NADA 141-299 Resflor Gold – original approval....
  • Freedom of Information Summary, 2011. NADA 141-328 Zactran Injectable Solution – original new animal drug application....
  • Freedom of Information Summary

    NADA 141-334 Zuprevo 18% – Original Approval

    (2012)
  • A.M. Glenny et al.

    Indirect comparisons of competing interventions

    Health Technol. Assess.

    (2005)
  • M. Hamm et al.

    Clinical efficacy of enrofloxacin against bovine respiratory disease comparing different treatment regimens

    Bovine Pract.

    (1999)
  • B. Hibbard et al.

    Dose determination and confirmation for ceftiofur crystalline-free acid administered in the posterior aspect of the ear for control and treatment of bovine respiratory disease

    Vet. Ther.

    (2002)
  • J.P. Higgins et al.

    Borrowing strength from external trials in a meta-analysis

    Stat. Med.

    (1996)
  • R. Highland et al.

    Dose determination and clinical evaluation of the efficacy of enrofloxacin injectable solution in the treatment of bovine respiratory disease

  • B.R. Hoar et al.

    A comparison of the clinical field efficacy and safety of florfenicol and tilmicosin for the treatment of undifferentiated bovine respiratory disease of cattle in western Canada

    Can. Vet. J.

    (1998)
  • G.K. Jim et al.

    A comparison of florfenicol and tilmicosin for the treatment of undifferentiated fever in feedlot calves in western Canada

    Can. Vet. J.

    (1999)
  • W.R. Kilgore et al.

    Therapeutic efficacy of tulathromycin, a novel triamilide antimicrobial, against bovine respiratory disease in feeder calves

    Vet. Ther.

    (2005)
  • P.W. Lockwood et al.

    Clinical efficacy of florfenicol in the treatment of bovine respiratory disease in Europe and North America

  • Cited by (41)

    • Bovine Respiratory Disease Considerations in Young Dairy Calves

      2022, Veterinary Clinics of North America - Food Animal Practice
    • A mixed treatment meta-analysis of antibiotic treatment options for bovine respiratory disease – An update

      2016, Preventive Veterinary Medicine
      Citation Excerpt :

      The prior distributions were originally based on the approach reported previously (Dias et al., 2011). For the original model we assessed σ ∼ U(0, 2) and σ ∼ U(0, 5), and that original analysis suggested σ ∼ U(0, 5) was preferred, we retained this prior in the updated model (O’Connor et al., 2013). The fit of the model was assessed based on the log odds ratio, by examining the residual deviance between the predicted values from the MTC model and the observed value for each study (Dias et al., 2010b).

    • Veterinary Medicine, Eleventh Edition

      2016, Veterinary Medicine, Eleventh Edition
    View all citing articles on Scopus
    View full text